Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVIN-II letrozole vs gonadotropins in PCOS
2024-519354-36-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of letrozole in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Live birth within 8 months after randomization. Planned start Aug 2025; status: authorised.
02
Drugs
letrozole
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2024-519354-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519354-36-00.